Theratechnologies Faces Potential Buyout with 75% Premium Amid Strategic Review and Multiple Bids from Future Pak
Future Pak's latest offer for THTX is $3.51/share in cash plus a CVR worth up to $0.99/share.
538 Views
No more insights
Sign in with Google
ENTITY
SMARTSCORE: 2.8/5
Theratechnologies (TH CN)
Theratechnologies (TH CN)
1
Analysis
Health Care • Canada
Theratechnologies, Inc. is a specialty pharmaceutical company that discovers and develops therapeutic peptide products, with an emphasis on growth-hormone releasing factor peptides. The Company's main product is being marketed in the United States for the reduction of excess abdominal fat n HIV-infected patients with lipodystrophy.
morex